DNA LINK, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,590 KRW | -1.33% |
|
-8.16% | -11.15% |
| Sales 2022 | 16.98B 12.35M | Sales 2023 | 21.95B 15.96M | Capitalization | 54.47B 39.6M |
|---|---|---|---|---|---|
| Net income 2022 | -7.78B -5.66M | Net income 2023 | -5.6B -4.07M | EV / Sales 2022 | 3.51 x |
| Net cash position 2022 | 4.7B 3.41M | Net cash position 2023 | 2.24B 1.63M | EV / Sales 2023 | 2.38 x |
| P/E ratio 2022 |
-8.18
x | P/E ratio 2023 |
-9.01
x | Employees | 80 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.98% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.33% | ||
| 1 week | -8.16% | ||
| Current month | -12.20% | ||
| 1 month | -15.08% | ||
| 3 months | -19.44% | ||
| 6 months | -28.06% | ||
| Current year | -11.15% |
1 week
2 565.00
2 785.00
1 month
2 315.003 050.00
Current year
2 315.003 500.00
1 year
2 315.004 510.00
3 years
2 315.007 450.00
5 years
2 150.0033 650.00
10 years
2 150.0033 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Eun Lee
CEO | Chief Executive Officer | 61 | 00-03-14 |
Hee-Joong An
BRD | Director/Board Member | 56 | - |
Young-Seok Ahn
AUD | Comptroller/Controller/Auditor | 65 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Eun Lee
CEO | Chief Executive Officer | 61 | 00-03-14 |
Young-Chan Park
BRD | Director/Board Member | 63 | - |
Hyeon-Il Choi
BRD | Director/Board Member | 69 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2,590 | -1.33% | 58,707 |
| 24-04-24 | 2,625 | -2.23% | 24,099 |
| 24-04-23 | 2,685 | -0.37% | 23,733 |
| 24-04-22 | 2,695 | -0.92% | 29,810 |
| 24-04-19 | 2,720 | -3.55% | 387,522 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
DNA LINK, INC. is a Korea-based company engaged in the genetics research business. The Company provides genome biomarkers excavation products through integrated genomic analysis and integrated clinical information analysis including high-quality data products according to genomic analysis, interpretation of analysis results, and technologies of molecular diagnostic kit production under the brand name of enhanced genome integration system (EGIS). The Company also provides personal genome analysis service products under the brand name of deoxyribonucleic acid personalized services (DNAGPS).
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.15% | 35.24M | |
| +1.85% | 42.59B | |
| +8.05% | 40.65B | |
| +48.83% | 40.57B | |
| -11.96% | 26.77B | |
| +8.75% | 24.81B | |
| -24.35% | 18.17B | |
| +28.11% | 12.05B | |
| -2.97% | 11.7B | |
| +7.59% | 11.1B |
- Stock Market
- Equities
- A127120 Stock
